The DCCT [2,3] and the Kumamoto study [4] provided further lines of evidence showing that, in both type 1 and type 2 diabetes, intensive insulin therapy is better able to prevent diabetic complications than conventional insulin therapy, with the added benefit of favorable HbA1c status achieved in patients given intensive insulin therapy. The gene discussed is INS; the disease is type 2 diabetes mellitus.